(Q34401542)

1 August 2017

1 reference

title

Telithromycin: an oral ketolide for respiratory infections (English)

1 reference

1 August 2017

D T Bearden

1

1 reference

1 August 2017

M M Neuhauser

series ordinal

2

1 reference

1 August 2017

K W Garey

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

21

1 reference

1 August 2017

issue

10

1 reference

1 August 2017

page(s)

1204-1222

1 reference

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Recent progress in novel macrolides, quinolones, and 2-pyridones to overcome bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group Streptococci isolated from blood of neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Use of ketolides in combination with other drugs to treat experimental toxoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

The site concentrations of antimicrobial agents in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Pneumococcal macrolide resistance--myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Short-Course antimicrobial therapy for upper respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Short course antibiotic therapy for respiratory infections: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Streptococcal Pharyngitis: Current Therapy and Criteria for Evaluation of New Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Epidemiological survey of bacterial resistance in upper respiratory tract infections in italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Antimicrobial susceptibility patterns of respiratory pathogens--a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Incidence of erythromycin resistance in Streptococcus pyogenes: a 10-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

The newer macrolides: azithromycin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Streptococcus pneumoniae: new tools for an old pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.15.1204.33902

10.1592/PHCO.21.15.1204.33902

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference